Please login to the form below

Tafinlar

This page shows the latest Tafinlar news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’ Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... This is good news for

Latest news

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year. Novartis’ cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent ... Tafinlar… particularly given the competition that of
Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. A phase III trial of Novartis Tafinlar and Mekinist has confirmed the potential of the pair in the post-surgical treatment of ... The combination of Novartis BRAF inhibitor Tafinlar
Novartis gets lung cancer OK for Tafinlar/Mekinist combo

The FDA has granted priority review to Tafinlar/Mekinist for the treatment of BRAF mutant NSCLC with disease progression on or after platinum-containing chemotherapy. ... Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with
J&J gets CHMP backing for broader Darzalex use

CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung
The UK's new Cancer Drugs Fund

Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.

More from news
Approximately 10 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Pharma deals during April 2014

GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Rheault started her career as a medicinal chemist at GlaxoSmithKline, where she was the inventor of Tafinlar.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Consultant: competitive salary

Vice President: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat: A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product: In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team: Enhanced expertise to deliver impactful internal training programmes for healthcare clients...